Mack Rachal, MD
Dermatology · Atlanta, GANPI 1902856370
Payments from drug & device makers
Across 662 payments — averaging $477.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$183K
- Helsinn Therapeutics (U.S.), Inc.$66K
- UCB SA$57K
- Novartis$3K
- Sanofi$2K
- Johnson & Johnson$1K
- plus $5K from 25 others
What the payments were for
- Consulting fees$5,2742%
- Speaking & faculty fees$214,93183%
- Travel & lodging$25,95710%
- Food & beverage$12,9055%
- Education$5020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 285 | $183,400 |
| Helsinn Therapeutics (U.S.), Inc. | 64 | $65,848 |
| UCB SA | 2 | $56,683 |
| Novartis | 12 | $2,671 |
| Sanofi | 23 | $1,693 |
| Johnson & Johnson | 41 | $1,015 |
| Lilly USA, LLC | 36 | $712 |
| Regeneron Healthcare Solutions, Inc. | 28 | $636 |
| UCB Biosciences Inc. | 14 | $629 |
| Galderma Laboratories, L.p. | 33 | $498 |
| UCB, Inc. | 24 | $474 |
| Sun Pharmaceutical Industries Inc. | 19 | $349 |
| Pfizer | 22 | $340 |
| Amgen | 14 | $300 |
| LEO Pharma Inc. | 11 | $174 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Incyte Corporation | 1 | $123 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 6 | $107 |
| Bristol Myers Squibb | 5 | $106 |
| Kyowa Kirin, Inc. | 3 | $53 |
| Dermavant Sciences, Inc. | 2 | $51 |
| Medimetriks Pharmaceuticals, Inc. | 2 | $49 |
| Organon | 3 | $42 |
| Novo Nordisk | 2 | $36 |
| EPI Health, LLC | 2 | $35 |
| Dermira, Inc. | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Dynavax Technologies Corporation | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$316,251 in reported general payments places this provider in the 95th percentile of 345 dermatology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 28 | $114,771 |
| OtezlaApremilast | 12 | $58,921 |
| Metronidazole | 335 | $15,416 |
| XolairOmalizumab | 12 | $15,341 |
| Fluorouracil | 158 | $10,267 |
| Ammonium Lactate | 425 | $9,977 |
| Imiquimod | 255 | $9,514 |
| Clobetasol Propionate | 177 | $6,469 |
| Triamcinolone Acetonide | 397 | $5,559 |
| Doxycycline Hyclate | 349 | $5,448 |
| CiclopiroxCiclopirox Olamine | 90 | $4,476 |
| Hydrocortisone | 171 | $3,419 |
| Acitretin | 23 | $3,103 |
| Tretinoin | 33 | $2,392 |
| Betamethasone Valerate | 65 | $1,511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $300 | $58,92112 claims |
| Lilly USA, LLCOlanzapine | $712 | $12113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 345 dermatology providers in Georgia.
Other dermatology in Atlanta
- Jamie WeismanAtlanta$4.9M
- Zakiya RiceAtlanta$1.1M
- Joseph PayneAtlanta$722K
- Ron FeldmanAtlanta$483K
- Jack ArbiserAtlanta$453K
- Tunisia CorneliusAtlanta$210K
- Emily AltmanAtlanta$178K
- Hailey RouhanaAtlanta$157K
- Lauren OrensteinAtlanta$156K
- Sarah ChisolmAtlanta$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.